The role of TRUS prostate biopsy quantitative histology in predicting the risk of extraprostatic disease

European Urology, Supplement

Volumn 1, Issue 6, 2002, Pages 76-82

  Bertaccini, Alessandro ^a   Scattoni, Vincenzo ^b   Comercia, Francesco ^a   Martorana, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Biopsy; Carcinoma; Prostate; Staging; Transrectal ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; HISTOLOGY; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; TUMOR LOCALIZATION;

EID: 0036765274     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00059-3     Document Type: Article

References (41)

1. Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol 1988;16:100-5.
2. Narayan P, Tewari A. Systematic biopsy-based staging of prostate cancer: scientific background, individual variables, combination of parameters, and current integrative models. Semin Urol Oncol 1998; 16:172-81.
3. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
4. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason-score to predict pathological stage in men with localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445.
5. Epstein JI, Potter SR. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 2001;166:402-10.
6. De la Taille A, Katz A, Bagiella E, Olsson CA, O'Toole KM, Rubin MA. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999;54(6):1039-43.
7. Egan AJ, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997;21(12):1496-500.
8. Veltri RW, O'Dowd G, Orozco R, Miller CM. The role of biopsy pathology, quantitative nuclear morphometry and biomarkers in the preoperartive prediction of prostate cancer staging and prognosis. Semin Urol Oncol 1998;16:106-17.
9. Glossklaus DJ, Coffey CS, Shappel SB, Jack GS, Cookson MS. Prediction of tumor volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU 2001;88:722-6.
10. Gao X, Mohideen N, Flanighan RC, Waters WB, Wojcik EM, Leman CR. The extent of biopsy involvement has an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. J Urol 2000;164:1982-6.
11. Freedland SJ, Csathy GS, Doery F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biological failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002;167:516-20.
12. Glossklaus DJ, Coffey CS, Shappel SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002;167:2032-6.
13. Grossfeld GD, Chang JJ, Broering JM, Li Y, Lubeck DP, Flanders SC, et al. Understaging and undergrading in a contemporary series of patients undergoing radical prostatectomy: results from the cancer of the prostate strategic urologic research endeavor database. J Urol 2001;165:851-6.
14. D'Amico A, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, et al. Clinical utility of percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-72.
15. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation and preoperative serum prostate specific antigen. Cancer 2001;91:2196-204.
16. Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Chang JJ, Broering JM, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from capsure. Urology 2002;59:560-5.
17. Scherr DS, Eastham J, Ohori M, Scardino P. Prostate biopsy technique and indications: when, where and how? Semin Urol Oncol 2002;20:18-31.
18. Lee F, Bahn DK, Siders DB, Greene C. The role of TRUS-guided biopsies for determination of internal and external spread of prostate cancer. Semin Urol Oncol 1998;16:129-36.
19. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies: a histopatologic correlation with radical prostatectomy specimens. Cancer 1995;75:530-8.
20. Wills LM, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 1998;51:759-64.
21. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens. Lack of prediction of tumor significance for men with non-palpable prostate cancer. J Urol 2001;166:104-10.
22. Tigrani VS, Bhargava V, Shinohara K, Presti Jr GC. Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy. Urology 1999;54:689-93.
23. Huland H, Hammerer P, Henke RP. Preoperative prediction of tumor eterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination prostate specific antigen and the results of six systematic biopsies. J Urol 1996;155: 1344-7.
24. Ackerman DA, Barry JM. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993;150:1845-50.
25. Borboroglu PG, Amling CL. Correlation of positive prostate sextant biopsy locations to sides of positive surgical margins in radical prostatectomy specimens. Eur Urol 2001;39(6):648-53.
26. Bostwick DG, Qian J, Bergstralh E, Dundore P, Dugan J, Myers R, Oesterling JE. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996;155:1361-7.
27. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers analysis of preoperative parameters. Urology 1994;44(6):862-8.
28. Epstein JI, Chan DW, Sokoll LJ. Non-palpable stage Tlc prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160(Part 2):2407-11.
29. Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology 1995;45(6):987-92.
30. Bostwick DG, Grignon D, Hammond EH, Amin MB, Cohen M, Crawford D, et al. Predictive factors in prostate cancer. College of American Pathologists Consensus Statements 1999. Arch Pathol Lab Med 2000;124:996-1000.
31. Bostwick DG, Foster CS, Algaba F, Hutter RVP, Montironi R, Mostofi FK, Prostate Tissue Factors. In: Murphy G, Denis L, Khoury S, Partin A and Denis L, editors. Proceedings of the Second International Consultation on Prostate Cancer, Co-sponsored by WHO and UICC, 27-29 June 1999. Paris (France): Plymbridge Distributors Ltd., 2000. p. 162-201.
32. Saliken JC, Gray RR, Donnelly BJ, Owen R, White LJ, Ali-Ridha N, et al. Extraprostatic biopsy improves the staging of localized prostate cancer. Can Assoc Radiol J 2000;51(2):114-20.
33. Deliveliotis CH, Varkarakis J, Trakas N, Louras G, Giannakopoulos S, Skolarikos A, et al. Influence of preoperative vesicle biopsy on decision for radical prostatectomy. Int Urol Nephrol 1999;31(1):83-6.
34. Vallancien G, Bochereau G, Wetzel O, Bretheau D, Debras B, Bougaran Y, et al. Biopsy of the seminal vesicles in the staging of localized cancer of the prostate: technic and result. Prog Urol 1997; 7(1):42-7.
35. Pandey P, Fowler Jr JE, Seaver LE, Feliz TP, Brooks JP. Ultrasound guided seminal vesicle biopsies in men with suspected prostate cancer. J Urol 1995;154(5):1798-801.
36. Terris MK, Pham TQ, Issa MM, Kabalin JN. Routine transition zone and seminal vesicles biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 1997; 157:204-6.
37. Takayama TK, Tisdale E, Bigler S. Indication for seminal vescicle biopsy in the evalution of prostate carcinoma. J Urol 1994;151(Suppl): 503A.
38. Okihara K, Kamoi K, Lane RB, Evans RB, Troncoso P, Babaian JR. Role of systematic ultrasound-guided staging biopsies in predicting extraprostatic extension and seminal vesicle invasion in men with prostate cancer. J Clin Ultrasound 2001;30:123-31.
39. Rogatsch H, Hittmair A, Reissigl A, Mikuz G, Feichtinger H. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997;182(2):205-10.
40. Veltri RW, Miller MC, Partin AW, Poole EC, O'Dowd GJ. Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer 2001;91(12):2322-8.
41. Chieco P, Bertaccini A, Giovannini C, Stecca BA, Martorana G. Telomerase activity in touch-imprint cell preparations from fresh prostate needle biopsy specimens. Eur Urol 2001;40:666-72.